HC Wainwright & Co. Maintains Buy on Edesa Biotech, Lowers Price Target to $10
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Vernon Bernardino maintains a 'Buy' rating on Edesa Biotech (NASDAQ:EDSA) but lowers the price target from $16 to $10.
August 15, 2023 | 10:57 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edesa Biotech's price target has been lowered from $16 to $10 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a short-term decrease in Edesa Biotech's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100